Skip to main content

Table 3 Biomarkers in patients with clinical cure and clinical failure

From: Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection

  Clinical cure Clinical failure P value
All patients (n = 249) n = 229 n = 20  
At presentation
 PCT 0.40 (0.13–1.54) 0.36 (0.10–1.46) 0.749
 PCT > 0.25 136 (59%) 12 (60%) 0.957
 CRP 120 (53–211) 90 (27–223) 0.851
 proADM 0.89 (0.62–1.30) 0.86 (0.67–1.20) 0.948
Day 3
 PCT 0.18 (0.07–0.87) 0.12 (0.04–0.69) 0.667
 PCT ≤ 0.25 122 (60%) 12 (67%) 0.568
 PCT ≤ 0.25 or PCT decline ≥80% 144 (71%) 14 (78%) 0.519
 proADM 0.66 (0.50–0.91) 0.63 (0.51–0.78) 0.667
Short treatment (n = 92) n = 82 n = 10  
At presentation
 PCT 0.34 (0.10–1.68) 0.36 (0.11–1.79) 0.980
 PCT > 0.25 47 (57%) 6 (60%) 0.871
 CRP 123 (53–194) 77 (15–142) 0.231
 proADM 0.76 (0.56–1.04) 0.85 (65–1.25) 0.360
Day 3
 PCT 0.12 (0.06–0.42) 0.13 (0.09–0.63) 0.794
 PCT ≤ 0.25 51 (66%) 7 (78%) 0.484
 PCT ≤ 0.25 or PCT decline ≥80% 62 (80%) 8 (89%) 0.542
 proADM 0.56 (0.47–0.76) 0.59 (0.53–0.74) 0.679
 Long treatment (n = 157) n = 147 n = 10  
At presentation
 PCT 0.48 (0.15–1.49) 0.48 (0.09–3.13) 0.826
 PCT > 0.25 89 (60%) 6 (60%) 0.973
 CRP 119 (52–224) 181 (37–263) 0.531
 proADM 0.98 (0.67–1.44) 0.86 (0.62–1.21) 0.495
Day 3
 PCT 0.22 (0.08–1.08) 0.08 (0.04–0.72) 0.358
 PCT ≤ 0.25 71 (56%) 5 (56%) 0.984
 PCT ≤ 0.25 or PCT decline ≥80% 82 (65%) 6 (67%) 0.899
 proADM 0.74 (0.53–1.03) 0.74 (0.47–1.02) 0.609
  1. Data presented as median (IQR) or number (%)
  2. CRP at presentation missing: n = 41 in short treatment and n = 41 in long treatment
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us